## US Family Health Plan Prior Authorization Request Form for Androderm, AndroGel, Natesto, Testim, Testosterone 1.62% gel, Vogelxo

To be completed and signed by the prescriber. To be used only for prescriptions which are to be filled through the Department of Defense (DoD) US Family Health Plan Pharmacy Program. US Family Health Plan is a TRICARE contractor for DoD.

The completed form may be faxed to 855-273-5735

OR

The patient may attach the completed form to the prescription and **mail** it to: Attn: Pharmacy, 77 Warren St, Brighton, MA 02135

## QUESTIONS? Call 1-877-880-7007

Step 1	Medication requested:			
Step	Please complete patient and physician information (please print):			
2	Patient Name:     Physician Name:       Address:     Address:			
	•	Phone #: e Fax #:		
Step	Please complete the clinical assessment:			
3	1. Is the requested medication being used for female-to- male gender reassignment (endocrinologic masculinization)?	☐ Yes SKIP to question 7	□ No Proceed to question 2	
	2. Is the patient a male who is greater than 17 years of age?	Yes Proceed to question 3	□ No STOP Coverage not approved	
	<ol> <li>Does the patient have a diagnosis of hypogonadism as evidenced by 2 or more morning total testosterone levels below 300 ng/dL?</li> </ol>	S  Q Yes Proceed to question 4	☐ No STOP Coverage not approved	
	4. Has the provider investigated the etiology of the low testosterone levels and acknowledges that testosterone therapy is clinically appropriate and needed?	Yes Proceed to question 5	☐ No STOP Coverage not approved	
	5. Is the patient experiencing symptoms usually associated with hypogonadism?	Yes Proceed to question 6	☐ No STOP Coverage not approved	
	6. Has the patient tried Fortesta (testosterone 2% gel) or testosterone 1% gel (Androgel 1% generic) for a minimum of 90 days AND failed to achieve total serum testosterone levels above 400 ng/dL (labs drawn 2 hours after Fortesta application) AND without improvement in symptoms?	Sign and date on page 2	☐ No SKIP to question 13	
	<ol> <li>Does the patient have a diagnosis of gender dysphoria made by a USFHP-authorized mental health provide according to most current edition of the DSM?</li> </ol>		☐ No STOP Coverage not approved	
	8. Is the patient 16 years of age or older?	Yes Proceed to question 9	☐ No STOP Coverage not approved	

## USFHP Prior Authorization Request Form for Androderm, AndroGel, Natesto, Testim, Testosterone 1.62% gel, Vogelxo

9.	Is the patient a biological female of childbearing potential?	Yes Proceed to question 10	☐ No SKIP to question 1
10.	Is the patient pregnant or breastfeeding?	☐ Yes STOP Coverage not approved	☐ No Proceed to question
11.	Has the patient experienced puberty to at least Tanner stage 2?	Yes Proceed to question 12	☐ No STOP Coverage not approv
12.	Does the patient have psychiatric comorbidity that would confound a diagnosis of gender dysphoria or interfere with treatment (for example: unresolved body dysmorphic disorder; schizophrenia or other psychotic disorders that have not been stabilized with treatment)?	☐ Yes STOP Coverage not approved	☐ No Proceed to question
13.	Does the patient have a contraindication or relative contraindication to Fortesta or testosterone 1% gel (Androgel 1% generic) that does not apply to the requested agent?	☐ Yes Sign and date below	☐ No Proceed to question
14.	Has the patient experienced a clinically significant skin reaction to Fortesta or testosterone 1% gel (Androgel 1% generic) that is not expected to occur with the requested agent?	☐ Yes Sign and date below	☐ No Proceed to question
15.	Is the request for Androderm or Natesto?	☐ Yes Proceed to question 16	☐ No STOP Coverage not approv
16.	Does the patient require a testosterone replacement therapy that has a low risk of skin-to-skin transfer between family members?	☐ Yes Sign and date below	☐ No STOP Coverage not approv
17.	Does the patient have a contraindication or relative contraindication to Fortesta or testosterone 1% gel (Androgel 1% generic) that does not apply to the requested agent?	☐ Yes Sign and date below	☐ No Proceed to question
18.	Has the patient experienced a clinically significant skin reaction to Fortesta or testosterone 1% gel (Androgel 1% generic) that is not expected to occur with the requested agent?	☐ Yes Sign and date below	☐ No Proceed to question
19.	Is the request for Androderm or Natesto?	Yes Proceed to question 20	☐ No STOP Coverage not approv
20.	Does the patient require a testosterone replacement therapy that has a low risk of skin-to-skin transfer between family members?	☐ Yes Sign and date below	□ No STOP Coverage not approv

 Step 4
 I certify the above is true to the best of my knowledge. Please sign and date:

 Prescriber Signature
 Date

 [27 July 2022]